OpenEvidence has reportedly raised $250 million at a valuation of $15 billion, only months after being valued at $12 billion. According to Business Insider, the latest investment came from Andreessen Horowitz and hospital systems, taking the medical AI company into a valuation bracket occupied by some of the world’s most closely watched technology businesses.

The number is striking because OpenEvidence is barely five years old and operates in a part of healthcare that, until recently, barely existed. Its product allows doctors to ask complex clinical questions in ordinary language and receive AI-generated answers grounded in medical literature, effectively placing a specialised medical search engine beside the clinician at the point of care.

Doctors have moved faster than hospitals

OpenEvidence describes itself as the fastest-growing application for physicians in history, and the adoption figures explain the confidence surrounding it. Business Insider reports that more than two-thirds of US doctors now use the product for diagnostic and treatment information, giving the company something considerably harder to build than an AI model: habitual use among clinicians.

That matters because healthcare technology has historically struggled to penetrate clinical workflows quickly. Hospitals can spend years procuring and implementing major software platforms, while OpenEvidence has grown through individual doctors choosing to use it as part of their everyday work.

The proposition is straightforward. Medical knowledge is expanding far faster than any individual clinician can reasonably absorb, with an estimated 1.5 million new medical papers published each year, while doctors are expected to make decisions using the latest available evidence. AI offers a way to compress that enormous body of knowledge into an interface capable of answering a specific question in seconds.

OpenEvidence has also secured access to some of medicine’s most valuable sources. Its partnerships include The New England Journal of Medicine, JAMA, Nature, Cochrane and the National Comprehensive Cancer Network, giving its answers access to clinical material that general-purpose internet search cannot necessarily reproduce.

$15 billion buys more than a medical chatbot

The valuation becomes more interesting when viewed against the wider race into healthcare AI. OpenAI, Anthropic, Google and Microsoft are all pushing deeper into medicine, while specialist companies are attempting to establish themselves before the largest AI platforms can absorb their functions.

OpenEvidence now sits directly in the middle of that contest. Business Insider reports that the company could be open to a sale, although no acquisition interest has been independently confirmed and OpenEvidence may ultimately remain independent.

For a large AI company, the attraction would be obvious. Buying OpenEvidence would provide immediate access to an established physician user base, medical publishing relationships and a product already embedded in clinical decision-making, rather than requiring years to build those relationships from scratch.

Its position is becoming more strategically interesting as the major AI laboratories move closer. Anthropic announced a partnership with OpenEvidence this month to expand AI-supported access to medical knowledge across around 100 countries, particularly where clinicians have limited access to journals, specialist expertise and continuing medical education.

The real prize is the clinical workflow

Healthcare AI has spent much of the past three years focused on administration. Ambient scribes, automated coding and documentation tools have attracted enormous investment because they address obvious inefficiencies without placing AI directly at the centre of a clinical decision.

OpenEvidence represents a more consequential stage of adoption. A doctor asking an AI system which treatment evidence applies to a patient, how guidelines have changed or what the literature says about a difficult presentation is using AI much closer to the intellectual core of medicine.

There is emerging evidence that specialised clinical systems can perform strongly in this environment. A 2026 study involving 149 practising physicians compared OpenEvidence with frontier general-purpose models across 620 real-world point-of-care questions and found that physicians rated the specialised system more highly across measures including accuracy, clinical utility, source quality and completeness.

That does not establish that an AI system should replace clinical judgement, nor does it eliminate the familiar problems surrounding hallucination, bias and incomplete evidence. It does suggest that the distinction between general-purpose AI and systems engineered specifically around clinical evidence may become increasingly important as hospitals decide which tools they are prepared to trust.

There is another business hiding underneath

OpenEvidence is free to verified clinicians in the US, which raises an obvious question about how a company reportedly worth $15 billion intends to make money. Its emerging answer is advertising, with pharmaceutical companies paying to reach doctors using the platform. That model deserves scrutiny precisely

‍